Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.
TLDR
An additional 10-yr update confirmed the previous report of an increased risk of second brain tumors in patients with pituitary adenoma treated with surgery and radiotherapy and should not preclude the use of radiotherapy as an effective treatment option.Abstract:
We assessed the risk of second brain tumors in a cohort of patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Four hundred and twenty-six patients (United Kingdom residents) with pituitary adenomas received radiotherapy at the Royal Marsden Hospital (RMH) between 1962 and 1994. They were followed up for 5749 person-years. The cumulative incidence of second intracranial tumors and systemic malignancy was compared with population incidence rates through the Thames Cancer Registry and the National Health Service Central Register (previously OPCS) to record death and the potential causes. Eleven patients developed a second brain tumor, including five meningiomas, four high grade astrocytomas, one meningeal sarcoma, and one primitive neuroectodermal tumor. The cumulative risk of second brain tumors was 2.0% [95% confidence interval (CI), 0.9-4.4%] at 10 yr and 2.4% (95% CI, 1.2-5.0%) at 20 yr, measured from the date of radiotherapy. The relative risk of second brain tumor compared with the incidence in the normal population was 10.5 (95% CI, 4.3-16.7). The relative risk was 7.0 for neuroepithelial and 24.3 for meningeal tumors. The relative risks were 24.2 (95% CI, 4.8-43.5), 2.9 (95% CI, 0-8.5), and 28.6 (95% CI, 0.6-56.6) during the intervals 5-9, 10-19, and more than 20 yr after radiotherapy (four cases occurred >20 yr after treatment). There was no evidence of excess risk of second systemic malignancy. An additional 10-yr update confirmed our previous report of an increased risk of second brain tumors in patients with pituitary adenoma treated with surgery and radiotherapy. The 2.4% risk at 20 yr remains low and should not preclude the use of radiotherapy as an effective treatment option. However, an increased risk of second brain tumors continues beyond 20 and 30 yr after treatment.read more
Citations
More filters
Journal ArticleDOI
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson,Edward R. Laws,Shlomo Melmed,Mark E. Molitch,Mohammad Hassan Murad,Andrea L. Utz,John A.H. Wass +6 more
TL;DR: This evidence-based guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including the appropriate biochemical assessment, a therapeutic algorithm, including use of medical monotherapy or combination therapy, and management during pregnancy.
Journal ArticleDOI
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
Rajesh V. Thakker,Paul J. Newey,Gerard V Walls,John P. Bilezikian,Henning Dralle,Peter R. Ebeling,Shlomo Melmed,Akihiro Sakurai,Francesco Tonelli,Maria Luisa Brandi +9 more
TL;DR: It is recommended that MEN1 patients and their families should be cared for by multidisciplinary teams comprising relevant specialists with experience in the diagnosis and treatment of patients with endocrine tumors.
Journal ArticleDOI
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Gary L. Francis,Steven G. Waguespack,Andrew J. Bauer,Peter Angelos,Salvatore Benvenga,Janete M. Cerutti,Catherine A. Dinauer,Jill Hamilton,Ian D. Hay,Markus Luster,Marguerite T. Parisi,Marianna Rachmiel,Geoffrey B. Thompson,Shunichi Yamashita +13 more
TL;DR: These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules.
Journal ArticleDOI
Guidelines for Acromegaly Management: An Update
Shlomo Melmed,Annamaria Colao,Ariel L. Barkan,Mark E. Molitch,Ashley B. Grossman,David L. Kleinberg,David R. Clemmons,Philippe Chanson,Edward R. Laws,Janet A. Schlechte,Mary Lee Vance,Ken K. Y. Ho,Andrea Giustina +12 more
TL;DR: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Book
The design and analysis of cohort studies
N. E. Breslow,N. E. Day +1 more
TL;DR: The scope ranges from an account of the elementary and descriptive approaches to cohort analysis to the fitting of regression models for incidence rates with general risk functions, and particular attention is given to the use of a case-control approach embedded in a cohort study.
Journal ArticleDOI
Radiation-induced second cancers: the impact of 3D-CRT and IMRT
Eric J. Hall,Cheng-Shie Wuu +1 more
TL;DR: IMRT is likely to almost double the incidence of second malignancies compared with conventional radiotherapy from about 1% to 1.75% for patients surviving 10 years, but the numbers may be larger for longer survival (or for younger patients), but the ratio should remain the same.